Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novavax sees weak Covid vaccine sales
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
Nov 12 (Reuters) -
Novavax
(
NVAX
.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi (SASY.PA), opens new tab.
Novavax sees weak Covid vaccine sales, convinced Sanofi can do better
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals and a pipeline of new vaccines it's now evaluating for R&D.
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine
The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused trials.
Hosted on MSN
1d
Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call Transcript
Novavax
, Inc. (NASDAQ:
NVAX
) Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good morning and welcome to ...
AOL
2d
Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals
Novavax
's (
NVAX
) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales ...
1d
Novavax price target lowered to $12 from $14 at BofA
BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...
Hosted on MSN
2d
Novavax falls after guidance cut on lower vaccine sales
Novavax
(NASDAQ:
NVAX
) shares lost ~12% in the premarket on Tuesday after the Gaithersburg, MD-based biotech, with its Q3 ...
3d
Novavax to Report Q3 Earnings: Here's What to Expect
On NVAX's third-quarter earnings call, investors will likely seek updates on management???s ongoing discussions with the FDA ...
Business Insider
1d
Novavax’s Market Share and Pipeline Uncertainties Lead to Sell Rating
J.P. Morgan analyst Eric Joseph maintained a Sell rating on
Novavax
(
NVAX
– Research Report) yesterday and set a price target of $9.00. Eric Joseph has given his Sell rating due to a combination ...
2d
Earnings Outlook For Novavax
Analysts are estimating that Novavax will report an earnings per share (EPS) of $-0.87. Anticipation surrounds Novavax's ...
1d
Novavax to Participate in Jefferies London Healthcare Conference
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
1d
Novavax: Balancing Potential and Risk Amid Strategic Shifts and Uncertain Market Outlook
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback